Overview

Gastroesophageal Reflux Disease Treatment Market is estimated to record a CAGR of over 4% during the forecast period 2020 to 2027.

The augmentation of the market can be credited to unhealthy lifestyle choices, rising awareness pertaining to GERD and technological advancements.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Gastroesophageal Reflux Disease Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Gastroesophageal Reflux Disease Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Gastroesophageal Reflux Disease Treatment Market:

• AstraZeneca
• Boston Scientific Corporation
• Eisai Co., Ltd.
• EndoGastric Solutions, Inc.
• EndoStim BV
• GlaxoSmithKline Plc.
• Ironwood Pharmaceuticals, Inc.
• Jeil Pharmaceutical Holdings Inc.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Gastroesophageal Reflux Disease Treatment Market Segmentation:

By Drug Class

• Antacids
• Proton Pump Inhibitors
• Rabeprazole
• Esomeprazole
• Lansoprazole
• Omeprazole
• Pantoprazole
• Dexlansoprazole
• Histamine-2 (H2) Blocker Receptor 
• Famotidine
• Cimetidine 
• Ranitidine
• Dopamine Receptor Antagonist

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Gastroesophageal Reflux Disease Treatment Market By Drug Class and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
       1.1 Objectives of the Study 
       1.2 Market Definition 
       1.3 Market Scope 
               1.3.1 Years Considered for the Study
               1.3.2 Market Covered
       1.4 Currency 
       1.5 Limitations 
       1.6 Stakeholders 

 2.  Research Methodology 
       2.1 Research Data 
              2.1.1 Secondary Data
                 2.1.1.1 Key Data from Secondary Sources
              2.1.2 Primary Data
                 2.1.2.1 Key Data from Primary Sources
       2.2 Market Size Estimation 
       2.3 Market Breakdown and Data Triangulation 
       2.4 Assumptions for the Study  

3. Executive Summary
       3.1 Market Outlook
       3.2 Segment Outlook
       3.3 Competitive Insights

4. Global Gastroesophageal Reflux Disease Treatment Market Variables, Trends & Scope
       4.1. Market Lineage Outlook
       4.2. Penetration and Growth Prospect Mapping
       4.3. Industry Value Chain Analysis
       4.4. Cost Analysis Breakdown
       4.5. Technology Overview
       4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances

5. Market Overview
       5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Gastroesophageal Reflux Disease Treatment Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Gastroesophageal Reflux Disease Treatment Market Analysis Tools
       6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
       6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
       6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
       6.4. Market Entry Strategies
       6.5. Case Studies

7. Global Gastroesophageal Reflux Disease Treatment Market, By Drug Class Historical Analysis and Forecast 2020-2027 (USD Million)
       7.1. Antacids
       7.2. Proton Pump Inhibitors
              7.2.1. Rabeprazole
              7.2.2. Esomeprazole
              7.2.3. Lansoprazole
              7.2.4. Omeprazole
              7.2.5. Pantoprazole
              7.2.6. Dexlansoprazole
       7.3. Histamine-2 (H2) Blocker Receptor 
              7.3.1. Famotidine
              7.3.2. Cimetidine 
              7.3.3. Ranitidine
       7.4. Dopamine Receptor Antagonist 

8.  North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       8.1. Introduction
       8.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            8.2.1. U.S.A
            8.2.2. Canada
            8.2.3. Mexico
       8.3. Market Size (USD Million) Forecast for North America 2020-2027

9. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       9.1. Introduction
       9.2. Regional Market Trends
       9.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            9.3.1. Brazil
            9.3.2. Venezuela
            9.3.3. Argentina
            9.3.4. Rest of Latin America
       9.4. Market Size (USD Million) Forecast for Latin America 2020-2027

10. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       10.1. Introduction
       10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            10.2.1. Germany
            10.2.2. U.K
            10.2.3. France
            10.2.4. Italy
            10.2.5. Spain
            10.2.6. Russia
            10.2.7. Poland
            10.2.8. Switzerland
            10.2.9. Rest of Western Europe

11. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       11.1. Introduction
       11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             11.2.1. Japan
             11.2.2. China
             11.2.3. Singapore
             11.2.4. India
             11.2.5. Australia and New Zealand
             11.2.6. ASEAN
             11.2.7. South Korea
             11.2.8. Rest of Asia Pacific
       11.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027

12. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       12.1. Introduction
       12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             12.2.1. Saudi Arabia
             12.2.2. UAE
             12.2.3. South Africa
             12.2.4. Egypt
       12.3. Market Size (USD Million) Forecast for MEA 2020-2027

13. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Technology Portfolio, Financial Layouts)
       13.1. AstraZeneca
                13.1.1. Company Overview
                13.1.2. Product Portfolio
                13.1.3. SWOT Analysis
                13.1.4. Financial Overview
                13.1.5. Strategic Overview
       13.2. Boston Scientific Corporation
                13.2.1. Company Overview
                13.2.2. Product Portfolio
                13.2.3. SWOT Analysis
                13.2.4. Financial Overview
                13.2.5. Strategic Overview
       13.3. Eisai Co., Ltd.
                13.3.1. Company Overview
                13.3.2. Product Portfolio
                13.3.3. SWOT Analysis
                13.3.4. Financial Overview
                13.3.5. Strategic Overview
       13.4. EndoGastric Solutions, Inc.
                13.4.1. Company Overview
                13.4.2. Product Portfolio
                13.4.3. SWOT Analysis
                13.4.4. Financial Overview
                13.4.5. Strategic Overview
       13.5. EndoStim BV
                13.5.1. Company Overview
                13.5.2. Product Portfolio
                13.5.3. SWOT Analysis
                13.5.4. Financial Overview
                13.5.5. Strategic Overview
       13.6. GlaxoSmithKline Plc.
                13.6.1. Company Overview
                13.6.2. Product Portfolio
                13.6.3. SWOT Analysis
                13.6.4. Financial Overview
                13.6.5. Strategic Overview
       13.7. Ironwood Pharmaceuticals, Inc.
                13.7.1. Company Overview
                13.7.2. Product Portfolio
                13.7.3. SWOT Analysis
                13.7.4. Financial Overview
                13.7.5. Strategic Overview
       13.8. Jeil Pharmaceutical Holdings Inc.
                13.8.1. Company Overview
                13.8.2. Product Portfolio
                13.8.3. SWOT Analysis
                13.8.4. Financial Overview
                13.8.5. Strategic Overview
       13.9. Johnson & Johnson 
                13.9.1. Company Overview
                13.9.2. Product Portfolio
                13.9.3. SWOT Analysis
                13.9.4. Financial Overview
                13.9.5. Strategic Overview
       13.10. Teva Pharmaceutical Industries Ltd.
                13.10.1. Company Overview
                13.10.2. Product Portfolio
                13.10.3. SWOT Analysis
                13.10.4. Financial Overview
                13.10.5. Strategic Overview

14. FutureWise SME key takeaway points for Client

Tables

Figures